Moreover, its expression in highly reactive cells close to the lesion sites, next to the blood–brain barrier, which is more permeable in MS patients, could facilitate the interaction of the putative pro-remyelinating compound and GPR17. The gene discussed is GPR17; the disease is myeloid sarcoma.